title: Suspension of milking in dairy cows produces a transient increase in milk lactoferrin concentration and yield after resumption of milking.
abstract: Lactoferrin is a multifunctional glycoprotein with a range of antimicrobial and immune-related properties that is found at >10-fold higher concentration in human milk (~1.7 g/L) relative to bovine milk (~0.15 g/L). Consumer demand is increasing for bovine lactoferrin through a wide range of nutritional and cosmetic consumer products. Increasing lactoferrin yield and concentration in bovine milk could assist in satisfying this increasing demand and may also help in increasing resistance to bovine mammary infection. Two experiments with cows in mid and late lactation were carried out to examine milking strategies to increase milk lactoferrin concentration and yield. Milking was suspended in cows normally milked twice daily, for periods of 2, 4, or 7d (mid lactation) or 2 or 4d (late lactation) after which cows were milked out and twice-daily milking resumed for 4d. In all groups, lactoferrin concentration was significantly increased during the remilking period, approaching concentrations similar to those found in human milk (~1 g/L). Lactoferrin yields were significantly higher in all treatment groups, although increasing the nonmilking period beyond 2d offered no advantage. Milk yield was lower initially after resumption of milking but recovered to preexperimental values by the fourth day of remilking in all groups, except the 4-d nonmilking group in late lactation. Milk somatic cell count was significantly elevated in all groups at the start of remilking but had substantially reduced by d 4 and reached a preexperimental level in the 2-d nonmilking group of mid-lactation cows. In summary, extended milking intervals can be used as a tool to produce a short-term increase in the concentration and yield of lactoferrin from bovine milk during established lactation, without any apparent long-term effects on milk yield and quality.
authors: Vialactia Biosciences Ltd., Newmarket, Auckland 1031, New Zealand. Electronic address: steve.davis@lic.co.nz.
authors: S R
authors: SR
authors: Davis
authors: Vialactia Biosciences Ltd., Newmarket, Auckland 1031, New Zealand.
authors: C R
authors: CR
authors: South
mesh_terms: D000818:Animals; D000890:Anti-Infective Agents; D002417:Cattle / Q000502:physiology*; D002452:Cell Count; D003612:Dairying / Q000379:methods*; D005260:Female; D006023:Glycoproteins; D007774:Lactation / Q000502:physiology*; D007781:Lactoferrin / Q000032:analysis*; D008892:Milk / Q000737:chemistry* / Q000166:cytology; D013535:Suspensions; D013997:Time Factors
chemical_list: D000890:Anti-Infective Agents; D006023:Glycoproteins; D013535:Suspensions; D007781:Lactoferrin
keywords: epithelium; lactation; mammary; milk synthesis